Main Sector
Pharma (fully integrated)
Subsectors
Antibodies
Anti-infectives
Generics
Peptides
Proteins
Small molecule therapeutics
Indications
Infectious and parasitic diseases / infectiology / parasitology
Neoplasms / cancer / oncology
Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Endocrine, nutritional and metabolic diseases / endocrinology
Mental and behavioural disorders / psychiatry /psychology
Diseases of the nervous system / neurology
Diseases of the eye / ophthalmology
Diseases of the ear / otology
Cardiovascular / cardiology
Respiratory / pulmonology
Digestive system / gastroenterology
Skin and subcutaneous tissue / dermatology
Musculoskeletal system and connective tissue / Orthopedics
Genitourinary system / Urology
Congenital malformations, deformations and chromosomal abnormalities / medical genetics
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Injury, poisoning and certain other consequences of external causes / toxicology
Social circumstances / substance related disorders / addiction
Products
In development: 177
On the market: 6
Description
Eli Lilly and Company is a global medicine company that discovers, develops, manufactures, and markets human pharmaceuticals across various therapeutic areas, including diabetes, oncology, immunology, and neuroscience. The company's products include JAYPIRCA®, a kinase inhibitor; REYVOW®, a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults, LYUMJEV®, a rapid-acting human insulin analog used to improve glycemic control in adult...
